CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma

CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma

IntroductionThe combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse...

Full description

Bibliographic Details
Main Authors:	Xiaofang Wu, Priya Srinivasan, Mousumi Basu, Talia Zimmerman, Samuel Li, Yin Wang, Pan Zheng, Yang Liu, Anthony David Sandler
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	CD24Fc tumor cell vaccine neuroblastoma immune-related adverse events autoimmune profiling
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1176370/full

Similar Items

Treatment of COVID-19 by CD24FC; a mini-review to the current knowledge
by: Ghazal Ghasempour Dabaghi, et al.
Published: (2021-01-01)

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
by: No-Joon Song, et al.
Published: (2022-01-01)

Fc multimers effectively treat murine models of multiple sclerosis
by: Jin Wang, et al.
Published: (2023-08-01)

The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies
by: Céline Monnet, et al.
Published: (2021-08-01)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
by: Sophia Roßkopf, et al.
Published: (2020-11-01)

“Ways in which the neonatal Fc-receptor is involved in autoimmunity”
by: Juliette Lamamy, et al.
Published: (2021-01-01)

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events
by: Jaume Mora, et al.
Published: (2023-01-01)

Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome observed in high-risk neuroblastoma
by: Tony A. Koehn, et al.
Published: (2012-05-01)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
by: Yihan Zhou, et al.
Published: (2023-06-01)

Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune Diabetes
by: Noémie Corcos, et al.
Published: (2021-08-01)

Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates
by: Andrew E Nixon, et al.
Published: (2015-04-01)

Importance of Fc Receptor γ-Chain ITAM Tyrosines in Neutrophil Activation and in vivo Autoimmune Arthritis
by: Tamás Németh, et al.
Published: (2019-02-01)

Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation
by: Fabian Junker, et al.
Published: (2020-07-01)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
by: Takuo Suzuki, et al.
Published: (2021-01-01)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
by: Peng Zhang, et al.
Published: (2017-11-01)

Los Neuroblastomas
by: Jean Michon, et al.
Published: (2019-09-01)

Olfactory Neuroblastoma
by: Ian C. Bickle
Published: (2016-06-01)

Olfactory Neuroblastoma
by: Jose M. Carnate
Published: (2010-12-01)

Surprising magic of CD24 beyond cancer
by: He Wang, et al.
Published: (2024-01-01)

Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
by: Elizabeth M. Bailey, et al.
Published: (2021-02-01)

Human CD4+ T-cells - A Role for Low Affinity Fc-receptors
by: Anil K Chauhan
Published: (2016-06-01)

Response to “High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma”
by: Francisco M. Vega, et al.
Published: (2020-03-01)

Neuroblastoma retroperitoneal del adulto
by: Fabio Croci, et al.
Published: (1983-04-01)

Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
by: Elizabeth A. Fitzpatrick, et al.
Published: (2020-03-01)

Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
by: Christophe Dumet, et al.
Published: (2023-03-01)

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
by: Andréa Cottignies-Calamarte, et al.
Published: (2023-02-01)

Inhibitory Fc-Gamma IIb Receptor Signaling Induced by Multivalent IgG-Fc Is Dependent on Sialylation
by: Christopher Beneduce, et al.
Published: (2023-08-01)

Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity
by: Myrthe A. M. van Delft, et al.
Published: (2023-04-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants
by: Robert Pejchal, et al.
Published: (2023-08-01)

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine
by: Sietse Q. Nagelkerke, et al.
Published: (2019-10-01)

Human Fcγ-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in lyme arthritis
by: Heike Danzer, et al.
Published: (2020-07-01)

High-Risk Neuroblastoma Treatment Review
by: Valeria Smith, et al.
Published: (2018-08-01)

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production
by: Cristina Capuano, et al.
Published: (2017-03-01)

Neuroblastoma
by: Comissão Nacional de Neoplasia da Infância
Published: (2023-08-01)

The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS
by: Ioannis Grigoropoulos, et al.
Published: (2024-04-01)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)

Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma
by: Hua Xie, et al.
Published: (2022-08-01)

Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology
by: Liang Zeng, et al.
Published: (2022-05-01)

Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease
by: Shiran Shapira, et al.
Published: (2023-12-01)